[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,683
  • Shares Outstanding, K 15,979
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,260 K
  • EBIT $ -43 M
  • EBITDA $ -43 M
  • 60-Month Beta -1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.99
  • Most Recent Earnings $-0.51 on 05/14/26
  • Next Earnings Date 08/10/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 1
  • High Estimate $-0.30
  • Low Estimate $-0.30
  • Prior Year $-2.07
  • Growth Rate Est. (year over year) +85.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8401 +1.93%
on 07/29/26
1.1307 -24.27%
on 07/01/26
-0.2537 (-22.86%)
since 06/30/26
3-Month
0.8401 +1.93%
on 07/29/26
2.1800 -60.72%
on 05/04/26
-1.1337 (-56.97%)
since 04/30/26
52-Week
0.8401 +1.93%
on 07/29/26
12.2300 -93.00%
on 10/15/25
-6.6837 (-88.64%)
since 07/30/25

Most Recent Stories

More News
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage...

TPST : 0.8563 (-0.86%)
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach Lead candidate TPST-4003 combines proprietary...

TPST : 0.8563 (-0.86%)
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors,...

TPST : 0.8563 (-0.86%)
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy...

TPST : 0.8563 (-0.86%)
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene...

TPST : 0.8563 (-0.86%)
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1)...

TPST : 0.8563 (-0.86%)
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting...

TPST : 0.8563 (-0.86%)
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support...

TPST : 0.8563 (-0.86%)
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Adds dedicated business development leadership to support Tempest’s strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions...

TPST : 0.8563 (-0.86%)
Tempest Reports Year End 2025 Financial Results and Provides Business Update

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...

TPST : 0.8563 (-0.86%)

Business Summary

Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 0.9137
2nd Resistance Point 0.9008
1st Resistance Point 0.8785
Last Price 0.8563
1st Support Level 0.8433
2nd Support Level 0.8304
3rd Support Level 0.8081

See More

52-Week High 12.2300
Fibonacci 61.8% 7.8791
Fibonacci 50% 6.5350
Fibonacci 38.2% 5.1910
Last Price 0.8563
52-Week Low 0.8401

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.